Why GLP-1 medications cause gallbladder problems: the bile acid science explained

TL;DR

A comprehensive 2025 review in Therapeutic Advances in Endocrinology and Metabolism explains three distinct molecular pathways through which GLP-1 medications increase gallbladder disease risk: suppression of cholecystokinin (CCK), disruption of the FXR and TGR5 bile acid signalling pathways, and downstream alterations to bile acid composition. Meta-analyses across 103,371 patients show a 37% higher relative risk of gallbladder disease. Women, older patients, and people with rapid weight loss are most vulnerable.

If you have ever wondered why GLP-1 medications come with a gallbladder warning on the label, the answer is more specific - and more interesting - than "it slows the gut." A 2025 review published in Therapeutic Advances in Endocrinology and Metabolism has done the most thorough mechanistic analysis to date, tracing three distinct molecular pathways from GLP-1 receptor activation to gallstone formation.

The three mechanisms behind GLP-1 gallbladder risk

Mechanism 1: CCK suppression and impaired gallbladder emptying

Cholecystokinin (CCK) is a hormone released from your small intestine in response to fat and protein in a meal. Its primary job is to trigger gallbladder contraction - squeezing bile into the digestive tract to help break down fats. Without regular CCK-driven contractions, bile sits in the gallbladder and stagnates.

GLP-1 medications reduce postprandial CCK release. Why? Because they slow gastric emptying - food arrives in the small intestine more slowly, so the intestinal cells that produce CCK get less stimulus at any given time. The result is a gallbladder that contracts less frequently and less forcefully, allowing bile to pool and concentrate. Concentrated bile is precisely the condition under which cholesterol crystallises into gallstones.

Mechanism 2: FXR and TGR5 pathway disruption

The farnesoid X receptor (FXR) is a nuclear receptor in the liver and gut that acts as a master regulator of bile acid metabolism. When activated by bile acids, FXR suppresses the enzymes CYP7A1 and CYP8B1 that produce bile acids, creating a feedback loop that keeps bile acid levels balanced. GLP-1 medications reduce FGF19 and GLP-2 production postprandially - both of which are needed to activate FXR signalling. Disrupted FXR means disrupted bile acid feedback, leading to oversaturated bile.

TGR5 is a bile acid receptor on the surface of gallbladder muscle cells. When activated by bile acids, it triggers the muscle to relax and then contract - part of the gallbladder's normal rhythmic emptying pattern. GLP-1 receptor activation has been shown to interfere with TGR5 signalling, reducing gallbladder contractility through the cAMP pathway. Less contractility means slower emptying, more bile stasis, and higher stone risk.

Mechanism 3: altered bile acid composition

When FXR signalling is disrupted and gallbladder emptying is impaired, the composition of bile changes. Bile becomes proportionally richer in cholesterol relative to bile salts and lecithin. When cholesterol concentration exceeds the capacity of bile to hold it in solution, it precipitates - literally falling out of suspension - and forms the crystals that nucleate into gallstones. Rapid weight loss accelerates this process: mobilising fat tissue floods the liver with fatty acids, which it converts to cholesterol and secretes into bile, further raising bile cholesterol saturation.

What the clinical data shows: a 37% higher relative risk

Beyond mechanisms, the review synthesised clinical evidence from multiple large studies:

• A meta-analysis of 76 randomised controlled trials involving 103,371 patients found GLP-1 medications associated with a 37% higher relative risk of gallbladder disease overall
• Cholelithiasis (gallstones) risk: 27% higher (RR 1.27)
• Cholecystitis (gallbladder inflammation): 36% higher (RR 1.36)
• Biliary disease overall: 55% higher (RR 1.55)

The risk scales with dose and duration. Higher-dose GLP-1 therapy carried an RR of 1.56. Longer treatment duration carried an RR of 1.40. Weight loss trials - where GLP-1 medications are pushed to maximum efficacy doses - showed the highest risk: RR 2.29. Diabetes trials, where doses are generally lower, showed RR 1.27.

Drug-specific differences in risk

The review also confirmed the drug-specific hierarchy identified in FAERS analyses:

• Liraglutide carries the strongest signal (ROR 6.75 in pharmacovigilance data)
• Semaglutide is close behind (ROR 5.74)
• Exenatide and tirzepatide show moderate signals
• Dulaglutide carries the weakest signal

An important nuance: a 2024 real-world study of 44,101 non-diabetic obese patients found GLP-1 medications were actually associated with reduced cholecystitis risk (OR 0.72) compared to controls. This contradicts the RCT data and highlights that real-world populations using lower doses or with different baseline risk profiles may not show the same signal. The evidence is not perfectly consistent - which is why the review emphasises individualised assessment rather than blanket warnings.

Who is most vulnerable?

The review identified a clear high-risk profile:

• Female sex - oestrogen increases cholesterol concentration in bile
• Age over 45
• Obesity at baseline - higher baseline cholesterol load in bile
• Rapid or large weight loss - concentrates bile cholesterol quickly
• Type 2 diabetes with insulin resistance
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• Personal or family history of gallstones
• Genetic variants in ABCG5 and ABCG8 cholesterol transport genes

Women and older patients dominate the highest-risk category. The same demographic - women over 50 with obesity - who most benefit from GLP-1 medications for weight loss and cardiovascular risk reduction are also the most vulnerable to gallbladder complications from treatment.

What mitigation looks like

The review proposes a three-tier monitoring approach based on individual risk:

• Low-risk patients: general counselling on gallbladder symptoms, dietary guidance (low-fat meals reduce CCK demand), routine follow-up
• Moderate-risk patients: baseline gallbladder ultrasound, enhanced patient education on warning symptoms, more frequent review
• High-risk patients: periodic imaging monitoring, consideration of prophylactic ursodeoxycholic acid (UDCA) - a bile acid that reduces cholesterol saturation - plus multidisciplinary team oversight

The practical advice for all GLP-1 users: avoid very high fat meals (which maximally stress gallbladder emptying), aim for gradual rather than extremely rapid weight loss, and know the warning symptoms of gallbladder disease - right upper abdominal pain, pain radiating to the right shoulder blade, pain after meals, fever, and jaundice. GLP-1 Shield supports the nutritional gaps that GLP-1 therapy creates, including magnesium, which plays a role in bile acid balance and gastrointestinal smooth muscle function.

Frequently asked questions

Why do GLP-1 medications increase gallstone risk?

GLP-1 medications increase gallstone risk through three distinct mechanisms: they suppress CCK release, which reduces gallbladder contraction frequency; they disrupt FXR and TGR5 bile acid signalling pathways that normally keep bile balanced; and they alter bile composition toward cholesterol supersaturation. Rapid weight loss adds a fourth mechanism by flooding the liver with cholesterol from mobilised fat stores, further oversaturating bile.

Which GLP-1 medication is safest for the gallbladder?

Based on available pharmacovigilance and trial data, dulaglutide (Trulicity) shows the weakest gallbladder signal. Tirzepatide (Mounjaro, Zepbound) shows a moderate signal but the fastest onset at 80 days. Liraglutide and semaglutide show the strongest associations. However, the lowest-risk option for any individual depends on their overall risk profile, comorbidities, and treatment goals - not the gallbladder signal alone.

Can ursodeoxycholic acid (UDCA) prevent gallstones on GLP-1 therapy?

UDCA is a bile acid that reduces cholesterol saturation and is used to dissolve cholesterol gallstones and prevent stone formation in high-risk groups (including after bariatric surgery). The 2025 review suggests UDCA as a consideration for high-risk GLP-1 users. It is not currently recommended for routine use in all GLP-1 patients, but for people with multiple gallstone risk factors, it is worth discussing with your prescriber.

How quickly do gallbladder problems develop on GLP-1 medications?

The median onset time across all GLP-1 drugs is 182 days - roughly six months. Tirzepatide has the fastest onset at a median of 80 days. This means most gallbladder events in clinical practice occur in the first six months to a year of treatment, rather than appearing only after long-term use. Staying alert to warning symptoms from the start of treatment - not just after months on the medication - is important.